Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-03-10 Board/Management Inform…
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Board/Management Information Classification · 95% confidence The document is an ad hoc announcement regarding a strategic organizational restructuring and the appointment of a new executive (Armin Metzger) to lead a newly created business unit. While it mentions personnel changes, the primary focus is on the strategic shift in the company's operational structure. According to the filing definitions, announcements regarding changes in senior management and board structure fall under the 'MANG' category.
2026-03-10 English
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Report Publication Announcement Classification · 100% confidence The document is an 'Ad-hoc announcement' from Sandoz Group AG detailing their full-year 2025 financial results. It provides key financial highlights, business performance, and future guidance. Crucially, it explicitly states 'Sandoz published its Integrated Annual Report 2025 today, which can be found here' and provides a link, indicating that this document is an announcement of the report rather than the full report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement.
2026-02-25 English
Sandoz confirms European Commission approval for Ranluspec (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Regulatory Filings Classification · 95% confidence The document is a media release from Sandoz Group AG announcing the European Commission's marketing authorization for a new biosimilar product, Ranluspec. It details the regulatory approval, the medical indications, and the strategic impact on the company's biosimilar portfolio. As this is a general corporate announcement regarding regulatory news that does not fit into specific financial reporting categories like 10-K, ER, or IR, it is classified as a Regulatory Filing (RNS).
2026-02-23 English
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Regulatory Filings Classification · 95% confidence The document is a media release from Sandoz Group AG announcing the European Commission's regulatory approval of a new biosimilar product, Ranluspec. It provides details on the product, the market, and the company's strategic outlook. Since it does not fit into specific categories like financial reports, shareholder meetings, or director dealings, and serves as a general corporate announcement regarding regulatory developments, it is classified as a Regulatory Filing (RNS).
2026-02-23 English
Sandoz receives US FDA approval to expand Enzeevu (aflibercept-abzv) label for multiple retinal indications
Regulatory Filings Classification · 95% confidence The document is a media release issued by Sandoz Group AG announcing that the US FDA has approved an expanded label for their product, Enzeevu. It follows the standard format of a corporate press release, providing details on the regulatory approval, product background, safety information, and contact details. It does not constitute a formal financial report, audit, or proxy statement, but rather a general regulatory and corporate announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-18 English
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Regulatory Filings Classification · 95% confidence The document is a media release from Sandoz Group AG announcing a regulatory approval from the US FDA for an expanded label of their product, Enzeevu. It follows the standard format of a corporate press release, providing details on the approval, product information, safety data, and contact information. Since it is a general regulatory announcement regarding company operations and product status that does not fit into more specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2026-02-18 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.